COLO B Coloplast A/S Class B

Coloplast appoints new President of its global Interventional Urology business

Coloplast appoints new President of its global Interventional Urology business

Effective January 2, 2023, Tommy Johns will enter a new role as President & Senior Vice President of Coloplast’s global Interventional Urology (IU) business, replacing Steve Blum, who has decided to retire at the end of 2022.

"Tommy has been with the company since 2015 and is the right person to lead our IU business going forward. He currently leads the IU Global Marketing & Innovation function, and as part of the global leadership team, he has helped bring the organization to where it is today. Tommy is a great ambassador for Coloplast and our company values and through his collaborative spirit he has built strong relationships not just in IU but across the Coloplast Group.” says Kristian Villumsen, Coloplast’s CEO.

Tommy Johns brings 30 years of experience in the medical device industry through his careers with Medtronic, Smiths Medical and Coloplast. He began his career with Coloplast in 2015 as Vice President and General Manager, Urology Care, North America, and was promoted the following year to Vice President of Global Marketing and Innovation, Interventional Urology.

"I am passionate about the work we do in Interventional Urology and I am excited to step into a new role. I look forward to leading our IU business into the future where we will bring existing and new products and solutions to more and more customers around the world. We are a purpose-driven growth business – and a great place to work," says Tommy Johns.

Tommy Johns replaces Steve Blum who has decided to retire after several successful decades in the global healthcare industry, including six years with Coloplast.

“Steve is a great leader with an impressive track record. He has successfully led the IU team through the pandemic, while simultaneously preparing the business for growth. Currently, we are seeing solid growth rates across IU and combined with the investments we have been making into innovation, the business is in a very good place. I want to thank Steve for his contributions to the company and wish him a happy retirement,” says Kristian Villumsen.

About Coloplast 

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare. Our business includes Ostomy Care, Continence Care, Wound and Skin Care, Interventional Urology and Voice & Respiratory Care. We operate globally and employ more than 14,000 employees.

Global Press Contact 

Peter Mønster, Senior Media Relations Manager 

 

 

   

U.S. Press Contact 

Kate Merwin, Head of Communications 

612-286-2455 

 



Attachments



EN
15/11/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coloplast A/S Class B

 PRESS RELEASE

Coloplast annoncerer ændringer i ledelsesteamet

Coloplast annoncerer ændringer i ledelsesteamet Coloplast offentliggør i dag ændringer til ledelsesteamet (ELT). Ændringerne omhandler Coloplasts urologiforretning og virksomhedens globale funktion for People & Culture. Leder af People & Culture, Dorthe Rønnau, har besluttet at forlade Coloplast for at starte et nyt kapitel i sin karriere. Dorthe Rønnau har haft forskellige roller på tværs af Coloplast-koncernen i næsten tre årtier. ”Coloplast har haft stor glæde af Dorthes værdier, integritet og stærke lederevner i hendes roller i Global Operations, Atos og People & Culture, og den øvers...

 PRESS RELEASE

Coloplast announces changes to Executive Leadership Team

Coloplast announces changes to Executive Leadership Team Today, Coloplast is announcing changes to the company’s Executive Leadership Team (ELT). The changes relate to the company’s Interventional Urology business as well as the global People & Culture function. Executive Vice President of People & Culture, Dorthe Rønnau, has decided to leave Coloplast to pursue the next chapter in her career. She has spent close to three decades in different roles across the Coloplast Group. “Dorthe’s values, integrity and strong leadership skills have benefitted the company across her roles in Global Op...

 PRESS RELEASE

Coloplast A/S - Beslutninger på den ordinære Generalforsamling 2025

Coloplast A/S - Beslutninger på den ordinære Generalforsamling 2025 I dag, den 4. december 2025, afholdt Coloplast A/S sin ordinære generalforsamling, hvor følgende beslutninger blev vedtaget: Årsrapporten for regnskabsåret 2024/25 blev godkendt.Forslag om udbetaling af udbytte for året på 18,00 kr. pr. aktie à nominelt 1 kr. blev godkendt. I tillæg til de 5,00 kr. pr. aktie à nominelt 1 kr., der blev udbetalt i forbindelse med Coloplast A/S’ halvårsresultat, bliver det samlede udbytte for regnskabsåret 2024/25 således 23,00 kr. pr. aktie à nominelt 1 kr.Vederlagsrapporten for regnskabsåre...

 PRESS RELEASE

Coloplast A/S - Decisions at the Annual General Meeting 2025

Coloplast A/S - Decisions at the Annual General Meeting 2025 Today, 4 December 2025, Coloplast A/S held its Annual General Meeting, at which the following resolutions were adopted: The annual report for the financial year 2024/25 was approved.Distribution of year-end dividend of DKK 18.00 per share of nominally DKK 1 was approved. In addition to the interim dividend of DKK 5.00 per share of nominally DKK 1 paid out in connection with Coloplast A/S’ half- year result, this brings the total dividend paid for the financial year 2024/25 to DKK 23.00 per share of nominally DKK 1.The remuneratio...

 PRESS RELEASE

Coloplast A/S - Indkaldelse til ordinær generalforsamling 2025

Coloplast A/S - Indkaldelse til ordinær generalforsamling 2025 Indkaldelse til ordinær generalforsamling 2025 Den ordinære generalforsamling i Coloplast A/S afholdes torsdag den 4. december 2025 kl. 15:30 på Coloplast A/S’ adresse, Holtedam 3 (Aage Louis-Hansen Auditorium), Humlebæk, Danmark. Indkaldelsen til den ordinære generalforsamling er vedlagt.     For yderligere information, kontakt venligst Investorer og analytikereAnders Lonning-SkovgaardExecutive Vice President, CFOTlf. 4911 1111 Kristine Husted MunkSr. Director, Investor RelationsTlf. 4911 1800 / 4911 3266Email: Simo...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch